Compare CLOV & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLOV | NUVB |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2020 | 2020 |
| Metric | CLOV | NUVB |
|---|---|---|
| Price | $4.88 | $4.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $5.38 | ★ $13.00 |
| AVG Volume (30 Days) | 4.1M | ★ 5.1M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.03 | ★ 71.56 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $1,924,308,000.00 | $62,902,000.00 |
| Revenue This Year | $53.58 | $211.79 |
| Revenue Next Year | $19.34 | $45.15 |
| P/E Ratio | $45.80 | ★ N/A |
| Revenue Growth | 40.34 | ★ 698.96 |
| 52 Week Low | $1.58 | $3.36 |
| 52 Week High | $5.59 | $9.75 |
| Indicator | CLOV | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 61.59 | 29.49 |
| Support Level | $4.10 | $4.10 |
| Resistance Level | $4.88 | $5.16 |
| Average True Range (ATR) | 0.21 | 0.24 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 68.64 | 20.80 |
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.